Veteran executive Eileen Voynick has been elected to the board of Fort Worth-based Omnicell Inc., a leader in transforming the pharmacy care delivery model.
Voynick fills the vacancy resulting from the departure of Sara J. White, a Class I director who stepped down from the board effective Jan. 5.
“We’re pleased to welcome Eileen to the Omnicell board of directors,” Randall Lipps, founder, chairman, president, and CEO of Omnicell, said in a statement. “Eileen is a widely respected leader with significant experience in the software, technology, and healthcare industries, as well as a proven track record creating value for stockholders, accelerating growth, driving operational excellence, and developing global businesses. I am confident that her skills will complement and strengthen our board as Omnicell continues to focus on driving long-term value and delivering outcome-centric innovations to improve patient outcomes.”
The company also announced that Vance Moore will not stand for re-election to its board and that the size of the board will be reduced from 10 to nine directors.
Voynick was most recently CEO of Sparta Systems
Voynick brings more than three decades of experience driving sales and operations at global industry leaders, including in the healthcare technology industry, at the executive and board level.
Most recently, she was CEO of Sparta Systems, a leading provider of enterprise-quality management software solutions. Before that, Voynick was chief operating officer at Allscripts Healthcare Solutions, EVP of global sales, services, and support at Misys Healthcare Systems, and in various management positions at Oracle, SAP, Siebel Systems, Gartner, Ariba, and Accenture.
She is board chair of AGS Health LLC, a revenue cycle management provider, and has held board positions for several other organizations, including Skydeck Acquisition Corp., CDK Global, Inc., r3, Advanced MD Health, Jefferson Health, Philadelphia University, and Thomas Jefferson University.
“I’d like to thank Sara and Vance for their dedication and outstanding contributions to the board. Over the years, they have provided valuable insights and counsel to support Omnicell in furthering our strategy,” Lipps said.
Voynick says her background will be important in her board service.
“Omnicell is at the forefront of delivering mission-critical medication management solutions, and I am honored to join the board,” Voynick said. “As hospitals and health systems are relying on technology now more than ever to serve patients, I look forward to leveraging my background in software, healthcare, and operations and working alongside Randall and the rest of the board as we continue to further our innovation agenda for the benefit of our customers and enhance stockholder value.”
Voynick has been appointed to the board’s corporate governance committee, Omnicell added.
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.